Loading...
XKRX019175
Market cap342mUSD
Dec 27, Last price  
15,600.00KRW
1D
-0.94%
1Q
-19.68%
Jan 2017
292.58%
Name

Shinpoong Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XKRX:019175 chart
P/E
—
P/S
3.84
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
0.47%
Rev. gr., 5y
1.33%
Revenues
200.23b
-4.33%
165,922,224,000188,135,653,000217,255,761,000232,060,469,000229,693,072,190221,169,380,010215,962,840,330220,291,937,930195,950,486,360194,147,337,500184,998,400,350187,389,168,040189,721,696,060197,750,767,000189,237,234,930209,287,628,000200,228,582,500
Net income
-57.33b
L+62.35%
8,843,130,00012,051,001,00021,052,454,00021,734,263,00024,866,240,00014,377,490,0005,437,651,0003,349,617,3601,476,216,010-18,591,699,490904,889,0002,803,780,0005,323,827,0005,002,804,500-11,526,010,680-35,308,829,000-57,325,386,770
CFO
-24.85b
L-6.04%
9,765,566,00023,570,779,0009,818,846,00011,357,006,00028,726,635,85030,792,490,39011,453,530,130-48,156,6909,890,504,09018,959,223,22010,148,039,89032,054,460,36019,350,539,80020,062,347,350-71,027,968,120-26,443,578,950-24,847,572,600
Dividend
Dec 29, 2020115 KRW/sh
Earnings
Mar 19, 2025

Profile

Shin Poong Pharm.Co.,Ltd. manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products. It also provides active pharmaceutical ingredients; Pyramax, an anti-malarial drug; drugs for treating hypercholesterolemia, knee osteoarthritis and shoulder periarthritis, and surgical adhesion barrier; and over the counter products. The company also exports its products to approximately 50 countries. Shin Poong Pharm.Co.,Ltd. was founded in 1962 and is headquartered in Seoul, South Korea.
URL
https://shinpoong.co.kr/
IPO date
Jan 20, 1990
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
200,228,582
-4.33%
209,287,628
10.60%
189,237,235
-4.31%
Cost of revenue
212,836,444
302,052,044
159,135,279
Unusual Expense (Income)
NOPBT
(12,607,862)
(92,764,416)
30,101,956
NOPBT Margin
15.91%
Operating Taxes
3,830,735
527,292
2,540,366
Tax Rate
8.44%
NOPAT
(16,438,597)
(93,291,708)
27,561,591
Net income
(57,325,387)
62.35%
(35,308,829)
206.34%
(11,526,011)
-330.39%
Dividends
(5,156,094)
Dividend yield
0.31%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
45,932,476
1,486,762
968,046
Long-term debt
1,370,398
2,369,786
1,145,269
Deferred revenue
Other long-term liabilities
2,697,653
3,169,021
9,262,579
Net debt
(34,264,824)
(69,634,345)
(55,936,072)
Cash flow
Cash from operating activities
(24,847,573)
(26,443,579)
(71,027,968)
CAPEX
(14,888,220)
(6,228,996)
(5,614,957)
Cash from investing activities
(16,309,264)
43,196,977
49,027,961
Cash from financing activities
43,238,932
(1,868,611)
(6,418,020)
FCF
(13,010,092)
(98,164,769)
(12,047,745)
Balance
Cash
60,461,167
55,916,550
92,701,773
Long term investments
21,106,531
17,574,343
(34,652,386)
Excess cash
71,556,269
63,026,511
48,587,525
Stockholders' equity
61,192,072
130,632,215
154,433,136
Invested Capital
258,439,163
272,829,072
316,281,955
ROIC
9.20%
ROCE
8.25%
EV
Common stock shares outstanding
51,262
51,262
51,262
Price
13,520.00
-36.08%
21,150.00
-33.80%
31,950.00
-74.23%
Market cap
693,065,742
-36.08%
1,084,196,778
-33.80%
1,637,829,175
-73.76%
EV
659,997,235
1,016,813,475
1,584,060,405
EBITDA
(699,472)
(79,960,934)
42,777,245
EV/EBITDA
37.03
Interest
1,718,660
830,991
202,057
Interest/NOPBT
0.67%